Horizon Pharma (HZNP) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
November 7, 2018 7:00 AM EST-- Quarterly Net Sales Increased 20 Percent to $325.3 Million, a Record for the Company; Third-Quarter 2018 GAAP Net Income of $26.0 Million; Adjusted EBITDA of $149.9 Million --
-- Quarterly Orphan and Rheumatology Segment Net Sales Increased 25 Percent to $219.9 Million; Represented 68 Percent of Total Company Net Sales --
-- Third-Quarter 2018 KRYSTEXXA® Net Sales Growth of 64 Percent; Continue to Expect Full-Year 2018 Net Sales Growth of More Than 65 Percent --
-- Adapting KRYSTEXXA MIRROR Clinical Trial to Support Potential for Registration; Decision Follows Encouraging External Case Series Showing Markedly Improved... More
